CC
LGND icon

Corton Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Corton Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,165
Closed -$228K – 480
2023
Q2 		$228K Buy
+3,165
New +$237K 0.11% 288

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's LGND Position: Q3 2023 in Review

Corton Capital sold out of Ligand Pharmaceuticals (LGND) in Q3 2023, closing a stake of 3,165 shares — an estimated $228K sold.

Corton Capital first reported a position in LGND in Q2 2023 and held it in 1 quarter. The position peaked at $228K in Q2 2023. 196 funds tracked by Wall St. Rank hold LGND as of Q3 2023.

  • Corton Capital reported no remaining Ligand Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Corton Capital sold 3,165 Ligand Pharmaceuticals shares in Q3 2023, an estimated $228K.
  • Corton Capital first reported a position in Ligand Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Corton Capital's Ligand Pharmaceuticals position peaked at $228K in Q2 2023.
  • 196 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2023.

Based on Corton Capital's 13F filing for Q3 2023, filed 14 Nov 2023.